Ovarian Cancer | Specialty

HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates

January 11th 2020

Unmet Needs in the Management of HER2+ mBC

January 11th 2020

Treatment Strategies for Relapsed/Refractory HER2+ mBC

January 11th 2020

HER2+ BC: Selection and Management of Neoadjuvant Therapy

January 11th 2020

Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

Dr. Backes on Financial Toxicity Considerations in Ovarian Cancer

January 10th 2020

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

Dr. O'Malley on Remaining Questions in Ovarian Cancer

January 8th 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

The Development of Genetic Testing in Ovarian Cancer

January 7th 2020

Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.

Dr. Moore on Treatment for Patients With Ovarian Cancer Who Develop Resistance to PARP Inhibitors

January 3rd 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Success Breeds a Need for Oncology Trials That Tackle Real-World Questions

December 30th 2019

Placing the results of a single trial in the context of real-world, everyday practice is increasingly difficult because of the number of available options and the absence of studies that directly compare individual strategies.

Outlining Advances Made in Ovarian Cancer in Oklahoma City

December 25th 2019

We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.

Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

December 23rd 2019

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Dr. Crafton on the Impact of PARP Inhibitors in Recurrent Ovarian Cancer

December 21st 2019

Sarah Crafton, MD, discusses the impact of PARP inhibitors on patients with recurrent ovarian cancer.

Dr. O'Malley on Ongoing Clinical Trials Evaluating Immunotherapy in Ovarian Cancer

December 19th 2019

David O’Malley, MD, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.

Dr. Cosgrove on Retreatment With PARP Inhibitors in Ovarian Cancer

December 18th 2019

Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.

The Dividing Line for Germline Mutation Testing Is Often Arbitrary

December 18th 2019

Although hereditary cancer risk was defined solely by family history in the not-so-distant past, today increasingly robust data may help define an individual’s heightened lifetime risk based on the presence of specific molecular findings within the germline